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There is no consensus as to what symptoms or quality-of-life (QOL) domains should 
be measured as patient-reported outcomes (PROs) in ovarian cancer clinical trials. 
A panel of experts convened by the National Cancer Institute reviewed studies pub-
lished between January 2000 and August 2011. The results were included in and 
combined with an expert consensus-building process to identify the most salient 
PROs for ovarian cancer clinical trials. We identified a set of PROs specific to ovarian 
cancer: abdominal pain, bloating, cramping, fear of recurrence/disease progression, 
indigestion, sexual dysfunction, vomiting, weight gain, and weight loss. Additional 
PROs identified in parallel with a group charged with identifying the most important 
PROs across cancer types were anorexia, cognitive problems, constipation, diarrhea, 
dyspnea, fatigue, nausea, neuropathy, pain, and insomnia. Physical and emotional 
domains were considered to be the most salient domains of QOL. Findings of the 
review and consensus process provide good support for use of these ovarian cancer–
specific PROs in ovarian cancer clinical trials.
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Ovarian cancer is the leading cause of 
gynecologic cancer deaths in the United 
States (1). The majority of women are diag-
nosed with advanced disease. After exten-
sive cytoreductive surgery followed by 
combination taxane/platinum–based chem-
otherapy (2,3), most women develop recur-
rent disease and are managed with palliative 
chemotherapy. The disease and its treat-
ment give rise to a multitude of symptoms 
and substantial impairments in domains 
of quality of life (QOL). Knowledge of 
these symptoms and impairments should 
guide aggressive symptom management to 
improve patients’ overall and domain-spe-
cific QOL and monitor patients’ ability to 
tolerate and continue to receive treatment.
It is generally accepted that the valid 
assessment of symptoms and QOL impair-
ments requires the use of patient-reported 
outcomes (PROs) (4,5). In a clinical trial, 
PROs are a means of evaluating treatment 
benefit or risk in a way that complements 
the typical primary outcome of survival (5). 
Currently, there is no consensus on which 
specific PROs (ie, symptoms and other 
QOL domains) should be assessed in can-
cer clinical trials, including trials in ovarian 
cancer. In recognition of this, the National 
Cancer Institute’s Symptom Management 
and Health-Related Quality of Life 
Steering Committee initiated independent 
reviews of the published literature by expert 
panels and a data-driven consensus-seeking 
process designed to culminate in recom-
mendations for 1) a core set of symptoms to 
be assessed routinely in cancer clinical trials 
that include a PRO and 2) those symptoms 
and QOL domains to be routinely assessed 
in clinical trials for three specific cancer 
sites: ovary, head and neck, and prostate. 
This brief report summarizes the recom-
mended core set of symptoms and QOL 
domains for ovarian cancer clinical trials.
The expert panel was comprised of 
patient representatives and health profes-
sionals from gynecologic oncology, medical 
oncology, nursing, and psychology. In this 
brief communication, we present methodo-
logical detail unique to deriving the core set 
of symptoms and QOL domains for ovar-
ian cancer clinical trials. Detailed methods 
reflective of our data-driven, consensus-
building process, including the multistake-
holder clinical trial planning meeting and 
efforts before and after, are described in 
the companion article in this issue of the 
Journal by Reeve et al. (6).
Electronic database searches of journal 
articles from January 2000 through August 
2011 were conducted. The principal medi-
cal subject heading search terms used were 
“ovarian neoplasms” AND “quality of life” 
OR “symptoms” OR “clinical trials (phase 
II–IV). Study abstracts were screened based 
on two eligibility criteria: 1) publication in 
a peer-reviewed, English language jour-
nal; 2)  reporting of results based on the 
systematic assessment of patient-reported 
symptoms or QOL in ovarian cancer. The 
information extracted using a standardized 
form included study purpose and design, 
participant demographic and clinical char-
acteristics, and PROs, including the out-
come measures used, the prevalence and 
severity of symptoms assessed, and the 
QOL domains assessed.
A total of 1528 abstracts were identi-
fied, and 23 publications were ultimately 
included in the final analysis (Figure  1). 
Fourteen of these studies (7–20) originated 
in the United States, four studies (21–24) 
originated in Canada, four studies (25–28) 
originated in Europe, and one study (29) 
originated in Hong Kong. The stated 
purpose of the majority of studies was to 
evaluate the effect of active treatment on 
women’s symptom experience and/or QOL. 
The purpose of approximately one-third of 
the studies was to evaluate the psychomet-
ric properties of new or existing outcome 
measures of QOL and/or symptom experi-
ence in ovarian cancer. The remaining stud-
ies were observational in nature and aimed 
primarily to examine various psychosocial 
variables, including QOL and symptoms, in 
ovarian cancer patients or survivors. With 
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respect to study design, the 23 publications 
included 17 longitudinal studies, five cross-
sectional studies (10,11,14–16), and one 
study that pooled data across multiple time 
points (25). Among the longitudinal stud-
ies, three (12,13,20) were phase II clinical 
treatment trials, and 10 reported data from 
phase III trials (8,15–19,21,23,26,27).
Sample sizes ranged from 17 to 502 
patients. Ten studies (8–11,14,15,24,26,27,29) 
reported the sample’s mean age, with means 
ranging from 55 to 62 years, whereas eight 
studies (12,13,20–23,29) reported median 
age, ranging from 55 to 64  years. Across 
studies, the majority of patients had stage III 
or IV disease. Among the eight studies that 
included stage I disease in addition to stages 
II, III, and IV (8–10,14,24,25,27,28), all but 
one (27) were aimed at either evaluating a 
measure’s psychometric properties or exam-
ining select psychosocial variables. All of 
the studies involved women in active treat-
ment with chemotherapy, either for initial, 
refractory, or recurrent disease. A  minority 
of these studies involved women undergo-
ing initial treatment for their disease. Fifteen 
of the 23 studies reported patients’ Eastern 
Cooperative Oncology Group performance 
status; the majority included patients with 
a performance status score between 0 and 
2; four studies included a small percentage 
(between 0.5% and 7%) of patients with per-
formance score 3 (requiring rest in bed or 
chair for more than half of the waking day) 
(7,11,21,27).
Across studies, the Functional 
Assessment of Chronic Illness Therapy 
(FACIT) measurement system (30) and 
the European Organization for Research 
and Treatment of Cancer Quality of Life 
Questionnaire (EORTC-QLQ) (31) family 
of outcome measures predominated. The 
most commonly administered outcome 
measure from the FACIT measurement sys-
tem was the multidimensional Functional 
Assessment of Cancer Therapy (FACT)–
Ovarian (FACT-O) (7), which is comprised 
of the FACT–General (FACT-G) (30) plus a 
12-item ovarian cancer–specific scale. With 
respect to the EORTC-QLQ, six studies 
(22–24,26,27,29) used the core question-
naire (EORTC-QLQ-C30), a 30-item self-
report measure (31) of QOL that includes 
both one-item and multi-item symptom 
scales, and three studies (21,25,28) used a 
version of the provisional ovarian cancer–
specific module (EORTC-QLQ-OV28) 
(25), a subscale specific to ovarian can-
cer, in addition to the core questionnaire. 
Additionally, four studies (10,11,14,20) 
used either a commonly administered 
symptom checklist such as the Memorial 
Symptom Assessment Scale (32) or a 
symptom assessment measure such as the 
Symptom Representation Questionnaire 
for Assessing Cancer Symptoms (33).
Eight studies (10,11,14,15,20,22,25,28) 
supported the identification of particular 
symptoms based on prevalence and sever-
ity (see Supplementary Table  1, available 
online), including anorexia (appetite loss), 
dyspnea, fatigue, pain, cognitive problems, 
and insomnia, which are prevalent in ovar-
ian cancer as well as other cancer types. 
We also identified abdominal symptoms, 
including abdominal pain, bloating, nausea, 
vomiting, constipation, cramping, indiges-
tion, weight gain, and weight loss. This is 
consistent with the knowledge that abdom-
inal symptoms are frequently associated 
with the presence of advanced disease (34). 
Finally, we identified neuropathy, sexual 
dysfunction, and fear of recurrence/disease 
progression as PROs that were notewor-
thy in terms of prevalence and/or severity 
in ovarian cancer. Whereas more general 
states such as anxiety or worry are preva-
lent across cancer types, fear of recurrence 
or progression in ovarian cancer seems to 
reflect the high likelihood of disease recur-
rence. Similarly, sexual problems, although 
not uncommon in other types of cancer, in 
ovarian cancer reflect the anatomical and 
physiological realities of the disease and 
its treatment. These ovarian cancer–spe-
cific PROs and the symptoms common 
to most cancers also were supported in 
the literature by several studies (8,11,17–
19,22,23,26,27) focused on describing the 
effects of different treatment protocols on 
symptom experience and QOL. Still other 
studies (8,9,12–14,16,22) identified these 
symptoms as having a meaningful effect on 
function or QOL.
Eleven studies (8,9,12,13,15,16,18–
21,26) identified physical and emotional 
well-being domains of QOL as espe-
cially salient to women with ovarian can-
cer. Overall QOL was also differentially 
affected depending on the cancer treatment 
type (19,23), where worse physical and 
functional well-being had an adverse effect 
on overall QOL (9,12,13,16,22).
We used a data-driven, consensus-build-
ing process to identify the most important 
symptoms for women with ovarian can-
cer. Ten of these—anorexia, constipation, 
1528 potentially relevant abstracts and cross-references identified by
PubMed, CINAHL, PsycINFO, and manual search of reference lists
298 duplicate abstracts
1230 abstracts screened
104 studies obtained for
further review
1126 abstracts excluded (eg, symptoms,
quality-of-life results not reported; data 
reported insufficient for quantifying patient 
reported outcomes)
81 full-text articles excluded (see above)
23 studies reviewed; data 
abstracted; working group 
review and discussions x 3
Working group consensus regarding ovarian
cancer core symptoms and quality-of-life
domains
Figure 1. Study identification.
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diarrhea, dyspnea, fatigue, nausea, neu-
ropathy, pain, cognitive problems, and 
insomnia—are included in a core set of 
12 symptoms identified in a parallel pro-
cess by the group charged with identifying 
the most important symptoms across can-
cer types. We also identified several ovar-
ian cancer–specific symptoms: abdominal 
pain, bloating, cramping, fear of recurrence, 
indigestion, sexual dysfunction, vomit-
ing, weight gain, and weight loss. We also 
identified physical and emotional domains 
of QOL that appear to be most commonly 
affected by treatments for ovarian cancer. 
The panel recommends that researchers and 
clinicians consider including these symp-
toms and QOL domains in future ovarian 
cancer clinical trials.
Our review focused primarily on symp-
toms and other QOL domains among 
women with advanced disease, and chem-
otherapeutic trials for advanced ovarian 
cancer predominated. However, treatment 
continues to evolve, and we should antici-
pate that the nature of symptoms and 
QOL domains affected will evolve as well. 
Novel agents, beyond conventional cyto-
toxic chemotherapy, are increasingly being 
incorporated into the treatment paradigm 
(35), and exposure to biologic agents, for 
example, may result in a distinctly different 
profile of side effects than those typically 
seen with ovarian cancer treatment. For 
example, bevacizumab, an agent targeted 
at vascular endothelial growth factor, is 
associated with hypertension, proteinuria, 
and intestinal perforation. These adverse 
effects, uncommon among more conven-
tional agents, may have substantial acute 
and chronic sequelae and a relatively 
unique impact on QOL. Other antiangio-
genesis agents may be associated with other 
adverse effects, including peripheral edema 
and encephalopathy, effects not commonly 
associated with ovarian cancer treatment. 
Other targeted therapies, including poly 
ADP-ribose polymerase inhibitors, multi-
kinase inhibitors, insulin-like growth factor 
inhibitors, and monoclonal antibodies, are 
currently under investigation. As experi-
ence with these agents grows, so, too, will 
our knowledge of the prevalence and sever-
ity of symptoms and QOL impairments 
associated with these therapies.
The lack of data associated with biologic 
and other evolving therapies and the predom-
inance in the literature of studies involving 
advanced disease are but two limitations 
inherent in this work. Further, we recognize 
that any final selection of PROs for a trial 
will be driven by study-specific hypotheses, 
concerns related to patient burden, and avail-
able clinical trial resources [for a complete 
discussion of limitations and implementation 
considerations, see the companion article by 
Reeve et  al. (6)]. Nevertheless, the identifi-
cation of a core set of symptoms and QOL 
domains to be assessed in ovarian cancer 
clinical trials represents an important step 
forward in the science of PRO measurement 
by promoting the potential for increased 
consistency across trials.
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